DTP: Legal Insights for Pharma Communications

Life Sciences Partner Stephanie Trunk and Life Sciences Regulatory and Compliance Attorney Darshan Kulkarni delve into the nuances of direct-to-patient (DTP) and direct-to-consumer (DTC) models in the pharmaceutical industry.

On

This encompasses advertising on drug prices, the intricacies of cash pay programs, and the evolving role of pharmacy benefit managers (PBMs). They also discuss the Trump Administration’s most favored nation status, as well as regulatory challenges and the need for a unified strategy to tackle rising health care costs.

Highlights of the conversation include:

  • The prevalence of DTC advertising in the United States and its impact on drug sales.
  • How the Trump Administration’s stance on DTC advertising raises First Amendment concerns.
  • How the most favored nation status could reshape drug pricing strategies.
  • PBMs playing a critical role in managing drug costs but face scrutiny for their practices.
  • Why regulatory compliance is essential for companies engaging in DTP sales.

Contacts

Continue Reading